semaglutide kidney disease in patients with overweight or obesity and chronic without diabetes: a randomized double-blind placebo-controlled clinical trial Ozempic picks up FDA indication

Most patients describe the GLP-1 injection as a small pinch that lasts only a second or two

However, experts such as Lydia Alexander, MD, president of the Obesity Medicine Association (OMA) and Chief Medical Officer at Enara, argue that the risks of compounded peptide medications make them a dangerous alternative to approved GLP-1 drugs as they are often produced and sold illegally by unlicensed pharmacies and "bootleggers" taking advantage of drug shortages, potentially containing unknown or dangerous ingredients that could be ineffective or actively harmful to patients

M.PhuongL

Madsen P, Rasmussen HH, Leffers H, Honor B, Dejgaard K, Olsen E, Kiil J, Walbum E, Andersen AH, Basse B, Lauridsen J, Ratz G, Celis A, Vandekerckhove J, Celis J: Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin

Store Ozempic in the refrigerator between doses

An older GLP-1 with somewhat lower efficacy but potentially lower cost, especially as generic options approach